Background Lung cancer is one of the most common and deadly tumors around the world.
Targeted therapy for patients with certain mutations, especially by use of tyrosine kinase …

Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)-
rechallenged therapy for EGFR-mutant non-small cell lung cancer (NSCLC) patients who …

Background Gefitinib, as the first epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …

Background Recently, a variety of clinical trials have shown that apatinib, a small-molecule
anti-angiogenic drug, exerts promising inhibitory effects on multiple solid tumors, including …

Background Dual blockade of both EGFR and VEGFR pathways in EGFR‐mutant NSCLC
have shown enhanced antitumor efficacy versus EGFR‐TKIs alone. Apatinib is an orally …

Few pieces of evidence have been published on the use of Apatinib Mesylate (AM) against
EGFR-TKI resistance in lung adenocarcinoma (LA) patients. Here, we investigate the clinical …

Chemotherapy is the standard treatment of in advanced lung adenocarcinoma patients
without driver mutation. However, few drugs could be selected when diseases progressed …

Lung adenocarcinoma is the most common pathological pattern of lung cancer. During the
past decades, a number of targeted agents have been explored to treat advanced lung …

Background Blocking vascular endothelial growth factor receptor (VEGFR) pathway can
enhance the efficacy of EGFR-TKI in EGFRm NSCLC. ACTIVE is the first phase III study …

Background The purpose of this study was to investigate the anti-tumor activities and the
mechanisms of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase …